https://www.selleckchem.com/pr....oducts/cdk2-inhibito
8 ± 1.5 vs 7.6 ± 1.6 for Metformin and sitagliptin). Weight and BMI improved after the use of SGLT-2i (BMI 36.5 ± 4.8 before Ramadan and 33.7 ± 2.4 after Ramadan). There were no reported cases of urinary tract infection in the empagliflozin group. SGLT-2 inhibitors combined with metformin for patients with diabetes during Ramadan fasting is as effective, safe and well tolerated as DPP4 combined with metformin. SGLT-2 inhibitors combined with metformin for patients with diabetes during Ramadan fasting is as effective, safe and
Like
Comment
Share
